Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yue YuJianming YingWen ZhangWeihua LiYongkun SunLin YangChengxu CuiYixin ZengAiping ZhouPublished in: Asia-Pacific journal of clinical oncology (2019)
dMMR mCRC seems resistant to chemotherapy and cetuximab. Bevacizumab combined therapy shows a sign of potentially favorable outcome in this subtype.